Yazar "Albayrak, S." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Effect of spironolactone therapy in patients with impaired diastolic function
    (Elsevier Science Bv, 2007) Özhan, Hakan; Balaban, Yakup; Albayrak, S.; Kaya, A.; Ordu, Serkan; Sözen, Serhat Bahadır; Yazıcı, M.
    …
  • Küçük Resim
    Öğe
    THE IMPACT OF PIOGLITAZONE THERAPY ON GLYCEMIC CONTROL, BLOOD PRESSURE AND INFLAMMATORY MARKERS IN PATIENTS WITH DIABETES MELLITUS
    (Editura Acad Romane, 2010) Ordu, Serkan; Güngör, A.; Yüksel, H.; Alemdar, R.; Özhan, H.; Yazıcı, M.; Albayrak, S.
    Aim. The aim of our study was to investigate the effect of pioglitazone on glycemic and blood pressure control, on inflammation markers in diabetic patients. Patients and methods. Forty-nine diabetic patients who had been followed up as outpatients for 2.7 years and HbA1c was >7% were included in the study. The patients had never received thiazolidinedione therapy before. Clinical, metabolic variables, high-sensitive C-reactive protein (hsCRP), homocysteine (HCY) and asymmetric dimethylarginine (ADMA) levels were measured. 30 mg pioglitazone were administered. The patients were followed up for six months and all the measurements were re-evaluated for comparison. Results. Body mass index (BMI) significantly increased after treatment. Fasting glucose, HbA1c and HsCRP were decreased. Insulin resistance was improved and HOMA-IR index was decreased after pioglitazone treatment [8 (+/- 6.5) vs 4(+/- 3.1); p<0.00011. Pioglitazone improved lipid metabolism. Mean total cholesterol and LDL cholesterol levels were decreased and HDL cholesterol was increased after treatment. The decrease in triglyceride and homocysteine levels did not reach significance. Mean ADMA level did not change after therapy [0.62 (+/- 0.39) vs 0.61 (+/- 0.44); p=0.85]. Conclusion. Pioglitazone treatment in type 2 DM produced significant improvements in measures of glycemic control, plasma lipids, blood pressure and homocysteine levels. Pioglitazone had no influence on ADMA levels.
  • Küçük Resim Yok
    Öğe
    Mortality and coronary events in the Turkish Adult Risk Factor Survey 2006: Mortality is declining in women whereas overall prevalence of coronary heart disease is on the incline [TEKHARF 2006 taramasinda ölüm ve koroner olaylar: Kadinlarda mortalitede azalma, koroner kalp hastali?i genel prevalansinda artma]
    (2007) Onat, Altan; Albayrak, S.; Karabulut, A.; Ayhan, E.; Kaya, Z.; Küçükdurmaz, Z.; Tuncer, M.
    Objectives: We analyzed all-cause and coronary mortality, incidence and prevalence of coronary heart disease (CHD) in a cohort of the Turkish Adult Risk Factor Study which was surveyed in the summer of 2006 essentially in geographic regions other than Marmara and Middle Anatolia. Study design: The survey consisted of 1585 participants (776 men, 809 women; mean age 55.3±11.8 years), accounting for 49% of all living participants of the overall cohort. Information on death was obtained from first-degree relatives and/or health personnel of local health offices. Survivors were evaluated by history, physical examination, and 12-lead electrocardiography. New coronary event was defined as fatal or nonfatal myocardial infarction, new stable angina, and/or myocardial ischemia that had occurred after the former survey. Results: Of the participants, 946 were examined, 599 subjects were evaluated on the basis of information gathered, and 40 deaths (27 men, 13 women) were documented. Cumulative follow-up of the survey starting from 1990 increased to 45,490 person-years with the addition of 2,842 person-years. Fifteen deaths were attributed to CHD. Annual overall mortality and coronary mortality rates were 14.1 and 5.1 per 1000 adults, respectively. In the 45 to 74 years age bracket, overall mortality declined to 10.9 (p=0.09) and coronary mortality to 5.6 per thousand. A decreasing trend in mortality was pronounced in women. The mean age at death increased to 67.1 years in men, and to 75.9 years in women. The prevalences of CHD were found to be 3%, 11%, and 27% in age groups of 39-49, 50-59, and ?60 years, respectively, which corresponded to an estimated population of 2.75 million. Conclusion: In the 45 to 74 years age bracket, overall and coronary deaths show a decreasing trend, particularly in women, which extends the mean age at death. However, the prevalence of CHD specific to age groups continues to rise, as well.